A filter system for circulating tumor cells
Patent Information
- Application Number
- IN202041052774
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-12-03
- Publication Date
- 2026-10-06
AI Technical Summary
Current methods for detecting and isolating circulating tumor cells (CTCs) from blood are complex, time-consuming, and not suitable for general hospital settings due to their low concentration and the need for sample pre-treatment, limiting their effectiveness in cancer diagnosis.
A centrifugal-force-based lab-on-a-filter system (CLF prototype) with a CTC specific antibody-coated track-etched polycarbonate membrane for size-selective filtration, allowing for rapid, clog-free, and selective isolation of CTCs from whole blood without prior treatment, integrated with fluorescence microscopy for identification and quantification.
The system enables rapid, high-purity isolation and identification of CTCs, reducing manual handling and processing time, making it suitable for clinical settings and improving the accuracy of cancer diagnosis by allowing real-time analysis of CTCs in whole blood samples.
Abstract
Description
FIELD OF INVENTION:
[001] This invention relates to an ultrasensitive centrifugal-force-based lab-on-a-filter system (CLF prototype) for the capturing and identification of circulating tumor cells (CTCs) from the blood stream of cancer patient.BACKGROUND OF THE INVENTION:
[002] Tumor metastasis (a stage of cancer where cancer spreads through lymphatic vessel to other parts of the body) is the major cause of cancer-associated mortality. Circulating tumor cells (CTCs) are markers of cancer metastasis and its survival in metastatic in primary stage is useful during the prognosis. Despite the clinical importance and progress of CTC-based cancer diagnostics, it still remains extremely challenging to develop systems to count and to detect CTC in cancer patients as its presence is as low as 1-10 per mL of blood plasma. Few attempts have been done by different research groups to find out the way to identify the less number of vital markers present in blood. For instance, Zhendanet al (CN105699641A) used a similar approach for the selective identification of CTCs but none of them matches with the unique design strategies of the present invention. In another report, Masato et al (US20160074860A1) developed a prototype having three different chambers. However, the present invention is entirely different form these prior arts in terms of design, prototype and approach towards CTCs identification.
[003] Moreover, the currently available techniques such as microfluidic systems and immunoaffinity-based methods for enriching CTCs are extremely complex and time consuming which poses difficulty in implementing it in general hospital settings.
[004] In order to overcome the above drawback, present invention provides a centrifugal force based lab-on-a-filter system (CLF prototype) which is clog free, highly sensitive and selective towards the rapid isolation of viable CTCs from whole blood without sample pre-treatment. More particularly prototype model of present invention is entirely different and operation procedure is clog free, portable and easy to use.OBJECTS OF THE INVENTION:
[005] The principal object of this invention is to design and fabricate a centrifugal force based lab-on-a-filter system (CLF prototype).
[006] Another object of this invention is to develop the CLF prototype which is clog free, highly sensitive and selective towards the rapid isolation of viable CTCs from whole blood without prior sample treatment.
[007] A further object of this invention is to provide the CLF prototype which is equipped with antibody immobilized track etched polycarbonate (PC) membrane for target specific and size selective separation of CTCs for filtration of blood.
[008] In another object of this invention, the CLF prototype to be designed with special provision to use fluorescence microscopy for the identification and quantification of CTCs.
[009] In further object of this invention, the CLF prototype to be tested with different cancer patient blood samples to quantify its selectivity and sensitivity towards CTCs.SUMMARY OF THE INVENTION:
[0010] In view of the crucial role played by tissue biopsy in examining heterogeneous diseases like cancer, biomedical and clinical research community has integrated it with best treatment options for tailoring personalized diagnosis and efficient treatment. But the entire 'picture' of the tumor is often masked by less tumor accessibility due to clinical complication to obtain the tissue at the point of initial diagnosis as well as during the course of treatment. Moreover, invasive tissue biopsy data obtained from limited amount of collected tissues are often painful and biased which makes it difficult for conducting repeated diagnosis and hence can lead to wrong clinical decisions. Even though tumor tissue is regarded as the gold standard source for clinical molecular investigations, in light of its limitations to study the tumor genetics and dynamics, cancer driven materials circulating in the blood plasma has emerged as a potent alternative to overcome some of the above mentioned challenges. Thus, "liquid biopsy" has gained significant attention as promising diagnostic procedure for identification and quantification of cancer driven materials present in the blood stream.
[0011] Accordingly, the present invention relates to the development of an ultrasensitive centrifugal-force-based lab-on-a-filter system (CLF prototype) for the capturing and identification of circulating tumor cells from the blood stream of cancer patient. Figure 1 and Figure 4 represents the schematic diagram as well as the photograph of CLF prototype, comprising:(1) Blood sample loading chamber and lid;(2) CTC specific antibody coated filter membrane;(3) CTC filtration chamber(4) Waste residual blood storage chamberThe blood sample holding chamber is used for holding the whole blood before the filtration process. The CTC specific antibody coated filter membrane is used to specifically capture the CTCs among the other components of the blood like RBC, WBC and platelets etc. Since it is transparent, it is suitable for microscopic analysis after the filtration of blood. The CTC filtration chamber is designed to hold the CTC specific antibody coated filter membrane. It is having a porous washer at the bottom with pores of size around 5 mm to hold the filter membrane and allow the blood to pass through during filtration. The waste residual blood storage chamber is designed for collecting residual blood after filtration.
[0012] The present invention has fabricated a custom designed lab-on-a-filter system (CLF prototype) for the rapid real-time identification of CTC from whole blood of cancer patients. Moreover, the present invention has also introduced immunoaffinity based porous membranes for improving the specificity of a system of the present invention to distinguish the captured CTCs from the leucocytes present in the whole blood during the filtration process.
[0013] In one embodiment the present invention provides an ultrasensitive portable lab-on-a-centrifugal filter system for analysis and isolation of circulating tumor cells comprising (1) blood sample loading chamber; (2). CTC specific antibody coated filter membrane; (3) CTC filtration chamber; and (4) waste residual blood storage chamber.
[0014] In another embodiment provides the ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said blood sample holding chamber is portable, detachable, transparent, washable, autoclavable and reusable.
[0015] In yet another embodiment provides the ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said CTC specific antibody coated filter membrane consists of immobilized filter membrane.
[0016] In still another embodiment provides the ultrasensitive portable lab-on-a- centrifugal filter system as claimed in claim 1 wherein said CTC specific antibody coated filter membrane is easily mountable, detachable, transparent, hydrophilic and highly flexible.
[0017] In another embodiment provides the ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said CTC specific antibody coated filter membrane has uniform porosity for filtration.
[0018] In still another embodiment provides the ultrasensitive portable lab-on-a- centrifugal filter system as claimed in claim 1 wherein said CTC specific antibody coated filter membrane is suitable for microscopic analysis.
[0019] In yet another embodiment provides the ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claims 1 and 3 wherein said CTC specific antibody coated filter membrane having pores of size 10 μm for the size based filtration of CTC .
[0020] In further embodiment provides the ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claims 1, 3 and 4 wherein said CTC specific antibody coated filter membrane is a polycarbonate membrane coated with antibody.
[0021] In yet another embodiment provides the ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said CTC filtration chamber is designed to hold the filter membrane and is detachable, transparent, washable, autoclavable and reusable.
[0022] In still another embodiment provides the ultrasensitive portable lab-on-a-centrifugal filter system as claims 1 and 6 wherein said CTC filtration chamber is porous with pores of size 5 mm at the bottom to hold the said filter membrane.
[0023] In further embodiment provides the ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said waste residual blood storage chamber is designed for collecting residual blood and is detachable, transparent, washable, autoclavable and reusable.BRIEF DESCRIPTION OF THE DRAWING:
[0024] Figure 1 shows drawing of the different chambers of centrifugal prototype.
[0025] Figure 2 shows drawing of the cross-sectional view of centrifugal prototype with a view of the filter holder.
[0026] Figure 3 shows photograph of the centrifugal prototype fabricated based on the specified design strategy.
[0027] Figure 4 shows photograph of various components of CLF system.DESCRIPTION OF THE INVENTION:
[0028] Although, cancer is considered as a localized disease in its pre-mature stages, in certain types of cells, it often becomes innate when patient is symptomatic and result in metastasis, which accounts for 90% of cancer deaths in the world. There are thriving evidences that cancer cells are showered from the primary tumor cells into the circulating blood stream that finally gets deposited at various sites resulting in tumor growth in unexpected body parts. Thus, it becomes critical to identify and quantify the circulating tumor cells (CTCs) during the early stages of tumorigenesis. Recently, CTC has received tremendous attention as a hallmark analyte for non-invasive cancer diagnosis as a result of which more than 270 clinical trials have already been registered utilizing this biomarker. Thus,so far, FDA has approved only one technology, namely the Cell Search system for clinical usage. Although it can be used to detect CTCs, its success rate in identifying CTC is only 50% out of the patients tested with known metastasis. As an attempt to address this, the present invention has custom designed a point of care lab-on-a-filter (CLF prototype) system built on size and immunoaffinity based porous membranes for the rapid, real-time identification of CTCs from blood. The blood need not undergo any pretreatment to be used with this filter system. The CLF prototype system is clog free, highly sensitive and selective towards the rapid isolation of viable CTCs from whole blood. As compared to most of the immunoaffinity-based CTC isolation platforms, the main strength of the proposed lab-on-a-filter system is that it requires only 60 s to process 5 mL of whole blood samples. Moreover, because this platform does not require sample pre-treatment, unnecessary manual handling steps is not necessary to acquire viable CTCs with high purity.
[0029] In order to realize a robust and user-friendly CTC isolation platform that can be readily adapted to clinical settings, the present invention has developed a custom-designed portable centrifugal prototype based target specific and size selective lab-on-a-filter CTC identification system (CLF prototype) for the rapid isolation of CTCs with high purity. The centrifugal prototype is comprised of three independent chambers for whole blood sample loading (1), CTC filtration membrane and membrane holder (2), and waste residual blood storage (3). The lab-on-a-filter platform utilizes centrifugal force to rapidly transfer unprocessed whole blood samples from one of the centrifugal prototype chambers to another. Except the membrane filter all other components are reusable thus reducing the cost. Each chamber of centrifugal prototype is designed in a detachable fashion so that CTC filtration membrane can be easily mounted and removed for the follow-up optical image analysis and molecular characterization for the accurate identification and quantification of CTC from each sample. Compared with the commercially available CTC identification system, the lab-on-a-filter system can offer more effective fluid control because it does not require external interconnectors. Instead, only a simple centrifuge is needed to actuate the fluid flow. Such advantages of the lab-on-a-filter system allow for reduced manual handling steps between the filtration, staining, and identification processes. To selectively isolate CTCs based on size differences between CTCs and the surrounding hematologic cells, a track-etched polycarbonate (PC) membrane filter with pore size of the order of 10um is integrated on a lab-on-a-filter system. Taken together, the as-proposed lab-on-filter system will serve as a potential candidate for the accurate quantification of CTC, which may have huge impact in translational clinical research.
[0030] Accordingly, the present invention provides an ultrasensitive portable lab-on-a-centrifugal filter system for analysis and isolation of circulating tumor cells comprising(1)Blood sample loading chamber, (2) CTC specific antibody coated filter membrane, (3) CTC filtration chamber and (4) Waste residual blood storage chamber.
[0031] The blood sample holding chamber is portable, detachable, transparent, washable, autoclavable and reusable. The CTC specific antibody coated filter membrane consists of CTC specific antibody immobilized filter membrane made of polycarbonate is easily mountable, detachable, transparent, hydrophilic and highly flexible. It is suitable for microscopic analysis. It has uniform porosity for filtration. The CTC specific antibody coated filter membrane has pores of size 10 μm for the size based filtration of CTC and the CTC specific antibody coated filter membrane is a polycarbonate membrane coated with antibody. The CTC filtration chamber is designed to hold the filter membrane and is detachable, transparent, washable, autoclavable and reusable. The CTC filtration chamber is porous with pores of size around 5 mm at the bottom to hold the filter membrane. The waste residual blood storage chamber is designed for collecting residual blood and is detachable, transparent, washable, autoclavable and reusable.
Claims
1. An ultrasensitive portable lab-on-a-centrifugal filter system for analysis and isolation of circulating tumor cells comprising: (1). blood sample loading chamber; (2). CTC specific antibody coated filter membrane; (3) CTC filtration chamber; and (4) waste residual blood storage chamber2. The ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said blood sample holding chamber is portable, detachable, transparent, washable, autoclavable and reusable.
3. The ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said CTC specific antibody coated filter membrane consists of immobilized filter membrane.
4. The ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said CTC specific antibody coated filter membraneis easily mountable, detachable, transparent, hydrophilic and highly flexible.
5. The ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said CTC specific antibody coated filter membrane has uniform porosity for filtration.
6. The ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said CTC specific antibody coated filter membrane is suitable for microscopic analysis.
7. The ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claims 1 and 3 wherein said CTC specific antibody coated filter membrane having pores of size 10 μm for the size based filtration of CTC .
8. The ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claims 1, 3 and 4 wherein said CTC specific antibody coated filter membrane is a polycarbonate membrane coated with antibody.
9. The ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said CTC filtration chamber is designed to hold the filter membrane and is detachable, transparent, washable, autoclavable and reusable.
10. The ultrasensitive portable lab-on-a-centrifugal filter system as claims 1 and 6 wherein said CTC filtration chamber is porous with pores of size 5 mm at the bottom to hold the said filter membrane.
11. The ultrasensitive portable lab-on-a-centrifugal filter system as claimed in claim 1 wherein said waste residual blood storage chamber is designed for collecting residual blood and is detachable, transparent, washable, autoclavable and reusable.
